Credit Suisse Group set a $151.00 target price on TESARO, Inc. (NASDAQ:TSRO) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the stock. Morgan Stanley began coverage on shares of TESARO in a report on Friday. They set an overweight rating for the company. Leerink Swann reiterated an outperform rating and set a $152.00 price objective (up from $115.00) on shares of TESARO in a report on Monday. FBR & Co lifted their price objective on shares of TESARO from $133.00 to $151.00 and gave the company an outperform rating in a report on Tuesday, December 27th. Robert W. Baird reiterated an outperform rating and set a $127.00 price objective on shares of TESARO in a report on Thursday, December 22nd. Finally, Wedbush reiterated an outperform rating and set a $139.00 price objective on shares of TESARO in a report on Wednesday, December 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $120.47.

TESARO (NASDAQ:TSRO) traded up 6.460% on Thursday, reaching $156.475. 813,111 shares of the company’s stock traded hands. The stock’s market cap is $8.08 billion. The company’s 50 day moving average is $134.61 and its 200-day moving average is $107.12. TESARO has a 52-week low of $29.51 and a 52-week high of $157.77.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.92) by $0.06. The company earned $3.73 million during the quarter, compared to analyst estimates of $4.39 million. TESARO had a negative return on equity of 141.88% and a negative net margin of 798.68%. The company’s revenue for the quarter was up 4187.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.66) earnings per share. Equities analysts expect that TESARO will post ($7.41) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The correct version of this report can be viewed at http://www.dailypolitical.com/2017/01/13/tesaro-inc-tsro-given-a-151-00-price-target-at-credit-suisse-group.html.

In other news, SVP Martin H. Jr. Huber sold 190 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $136.26, for a total value of $25,889.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Martin H. Jr. Huber sold 327 shares of the business’s stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $121.29, for a total transaction of $39,661.83. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $223,416.18. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in TESARO by 16.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,584,279 shares of the biopharmaceutical company’s stock valued at $559,768,000 after buying an additional 776,709 shares during the period. Passport Capital LLC acquired a new stake in TESARO during the second quarter valued at about $61,720,000. FMR LLC raised its stake in TESARO by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock valued at $512,490,000 after buying an additional 531,892 shares during the period. Pictet Asset Management Ltd. raised its stake in TESARO by 661.3% in the second quarter. Pictet Asset Management Ltd. now owns 418,730 shares of the biopharmaceutical company’s stock valued at $19,387,000 after buying an additional 363,730 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in TESARO by 249.0% in the third quarter. Bank of New York Mellon Corp now owns 493,701 shares of the biopharmaceutical company’s stock valued at $49,490,000 after buying an additional 352,228 shares during the period. 97.40% of the stock is currently owned by institutional investors.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.